Quantum Biopharma Files 6-K Report
Ticker: QNTM · Form: 6-K · Filed: Mar 27, 2026 · CIK: 0001771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Mar 27, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer
TL;DR
Quantum Biopharma filed a 6-K on 3/27/26, standard foreign issuer report, no major news.
AI Summary
Quantum Biopharma Ltd. filed a Form 6-K on March 27, 2026, reporting information as a foreign issuer. The filing includes a press release as an exhibit, but no specific financial figures or operational updates are detailed in the provided text.
Why It Matters
This filing indicates routine reporting by Quantum Biopharma Ltd. as a foreign issuer, providing transparency to investors about its regulatory compliance.
Risk Assessment
Risk Level: low — The filing is a routine 6-K report for a foreign issuer and does not contain specific financial or operational disclosures that would indicate immediate risk.
Key Players & Entities
- Quantum Biopharma Ltd. (company) — Filer of the 6-K report
- 0001771885 (company) — CIK number for Quantum Biopharma Ltd.
- 2026-03-27 (date) — Filing date and period of report
FAQ
What type of report is Quantum Biopharma Ltd. filing?
Quantum Biopharma Ltd. is filing a Form 6-K, which is a report of a foreign issuer.
When was this Form 6-K filed?
The Form 6-K was filed on March 27, 2026.
What is the CIK number for Quantum Biopharma Ltd.?
The CIK number for Quantum Biopharma Ltd. is 0001771885.
What is the business address of Quantum Biopharma Ltd.?
The business address of Quantum Biopharma Ltd. is 55 UNIVERSITY AVENUE, SUITE 1003 TORONTO Ontario, Canada M5J 2H7.
Does the filing contain specific financial details or operational updates?
Based on the provided text, the filing primarily consists of the Form 6-K and an attached press release (EX-99.1), but specific financial figures or operational updates are not detailed in this excerpt.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2026-03-27 08:10:03
Filing Documents
- f6k_032626.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 16KB
- 0001171843-26-001969.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: March 27, 2026 /s/ Donal Carroll Donal Carroll Chief Financial Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated March 27, 2026